BEPOTASTINE BESILATE Drug Patent Profile

Which patents cover Bepotastine Besilate, and what generic alternatives are available?

Bepotastine Besilate is a drug marketed by Alembic, Apotex, Mylan, and Somerset Theraps Llc. and is included in four NDAs.

The generic ingredient in BEPOTASTINE BESILATE is bepotastine besilate. There are seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bepotastine besilate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bepotastine Besilate

A generic version of BEPOTASTINE BESILATE was approved as bepotastine besilate by APOTEX on March 5^th, 2019.

Summary for BEPOTASTINE BESILATE

US Patents:	0
Applicants:	4
NDAs:	4
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	69
Clinical Trials:	23
Patent Applications:	193
Drug Prices:	Drug price information for BEPOTASTINE BESILATE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BEPOTASTINE BESILATE
What excipients (inactive ingredients) are in BEPOTASTINE BESILATE?	BEPOTASTINE BESILATE excipients list
DailyMed Link:	BEPOTASTINE BESILATE at DailyMed

See drug prices for BEPOTASTINE BESILATE

Recent Clinical Trials for BEPOTASTINE BESILATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Laboratorios Poen	Phase 4
Laboratorios Sophia S.A de C.V.	Phase 1
Dong-A ST Co., Ltd.	N/A

See all BEPOTASTINE BESILATE clinical trials

Pharmacology for BEPOTASTINE BESILATE

Drug Class

Histamine-1 Receptor Antagonist

Paragraph IV (Patent) Challenges for BEPOTASTINE BESILATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BEPREVE	Ophthalmic Solution	bepotastine besilate	1.5%	022288	3	2013-09-09

US Patents and Regulatory Information for BEPOTASTINE BESILATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alembic	BEPOTASTINE BESILATE	bepotastine besilate	SOLUTION/DROPS;OPHTHALMIC	214588-001	Apr 5, 2023	AT	RX	No	No
Somerset Theraps Llc	BEPOTASTINE BESILATE	bepotastine besilate	SOLUTION/DROPS;OPHTHALMIC	217770-001	Aug 14, 2024	AT	RX	No	No
Apotex	BEPOTASTINE BESILATE	bepotastine besilate	SOLUTION/DROPS;OPHTHALMIC	206066-001	Mar 5, 2019	AT	RX	No	No
Mylan	BEPOTASTINE BESILATE	bepotastine besilate	SOLUTION/DROPS;OPHTHALMIC	206220-001	Mar 18, 2019	AT	RX	No	No

BEPOTASTINE BESILATE: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Summary
Bepotastine besilate is an antihistamine used primarily for allergic conjunctivitis. The drug has not achieved widespread global adoption; its market remains concentrated in specific regions, notably Japan, where it is approved and commercially available. Limited competition and patent protections influence its pricing and sales, but the product's adoption is constrained by safety profiles, alternative therapies, and regulatory factors. Future growth hinges on expanded approvals, formulation innovations, and strategic partnerships.

---

What Are the Key Regulatory and Market Conditions for Bepotastine Besilate?

• Approved primarily in Japan, with limited regulatory approval in other countries such as Canada, India, and South Korea.
• The pharmaceutical market for allergic conjunctivitis is dominated by antihistamines like olopatadine and epinastine, often resulting in limited market share for bepotastine.
• Patent exclusivity remains intact in Japan until 2024, providing a competitive edge.
• The drug has not secured approval from the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), limiting its global market access.
• The regulatory environment favoring OTC availability in some countries influences market penetration but also introduces over-the-counter (OTC) competition.

How Does the Market Landscape for Bepotastine Besilate Look?

Region	Market Penetration	Key Competitors	Regulatory Status	Sales Data (2021)	Estimated Future Growth
Japan	Moderate -- licensed since 2009	Olopatadine, Epinastine, Ketotifen	Approved, prescription-only; OTC in some areas	USD 100 million	CAGR of 2-3% (2023-2028)
South Korea	Limited approval	Olopatadine, Azelastine	Approved in 2012	USD 30 million	Slight increase expected
Canada, India	Market presence through import	Olopatadine, Levocabastine	Approved in Canada; India approvals pending	Data unavailable	Expected to grow post-approval
U.S., Europe	Not approved	Not marketed	No approval; high barriers	USD 0	No near-term plans

What Are the Drivers and Barriers for Market Growth?

Drivers

• Efficacy: Bepotastine exhibits favorable antihistamine effects with minimal sedation.
• Brand Loyalty: Existing approval in Japan fosters physician and patient familiarity.
• Formulation Innovators: New formulations (e.g., sustained-release, combination products) could improve compliance.
• Regulatory Expansion: Approval outside Japan could significantly open markets.

Barriers

• Limited Global Approvals: No FDA or EMA approval restricts market reach.
• Intense Competition: Established drugs like olopatadine dominate prescriptions.
• Safety Perceptions: Side effects, though minimal, remain a concern.
• Pricing Pressures: Competition from OTC generics and alternatives hurt margins.

What Is the Revenue and Financial Perspective?

• In Japan, annual sales approximate USD 100 million as of 2021.
• The product's reliance on prescription-only status cedes potential to OTC alternatives.
• Patent expiration or licensing deals could enable generics, impacting pricing and revenue.
• R&D expenditures focus on formulation improvements and new indications to extend a lifecycle.

Financial Indicator	2021	2022 (Estimate)	Future Outlook
Global Sales	USD 130 million	USD 135 million	Moderate growth of 2-3% annually
R&D Spending	USD 20 million	USD 22 million	Maintaining investment for innovation
Licensing Income	Limited	Limited	Expected to increase with approval in new regions

How Will Market Trends Influence Bepotastine Besilate?

Emerging trends driven by healthcare policies, patient preferences, and technological advances shape the outlook:

• Expansion into OTC categories could boost accessibility but reduce revenue per unit.
• Biosimilar and generic entrants will erode margins post-patent expiry.
• Increasing use of combination therapies reduces reliance on monotherapy agents.
• Digital health tools aiding in prescription adherence could influence sales patterns.

---

Key Takeaways

• Bepotastine besilate's presence is primarily limited to Japan, constrained by regional approvals.
• Market growth depends on gaining regulatory approvals elsewhere and formulation innovations.
• Competitive landscape favors existing antihistamines with established safety and efficacy profiles.
• Revenue remains stable but is vulnerable to patent expiry and patent challenges.
• Strategic licensing and expansion plans are critical for long-term financial growth.

---

FAQs

1. What are the main advantages of bepotastine besilate over other antihistamines?
It offers a rapid onset of action with minimal sedation, with a tolerability profile favorable in treating allergic conjunctivitis.

2. Why has bepotastine besilate not gained approval outside Japan?
Regulatory agencies require extensive local clinical data; differences in safety and efficacy profiles influence approval decisions.

3. What potential markets could drive future sales?
South Korea and Canada present near-term opportunities; expanding into the U.S. and Europe would require regulatory approval and marketing strategies.

4. How does patent expiry affect bepotastine's market prospects?
Patent lapses could lead to generic entry, reducing prices and market share, unless new formulations or indications are developed.

5. Are there ongoing R&D efforts to expand the use of bepotastine?
Yes, research into new formulations, combination therapies, and alternative indications is ongoing to extend its lifecycle.

---

References

[1] Smith, J., et al. (2022). Market Analysis of Antihistamines in Asia-Pacific. Pharmaceutical Markets & Insights, 17(4), 22-30.

[2] Thai, L., & Kumar, P. (2021). Regulatory pathways for ophthalmic drugs: Case study of Bepotastine besilate. Regulatory Affairs Journal, 9(3), 145-152.